Alejandro Prado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alejandro Prado has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Eduardo Cabello
Radiation Oncology Department, Radiotherapy Section, HU 12 de Octubre, Madrid, Spain
3 shared publicationsRaúl Díaz
Radiation Oncology Department, Radiotherapy Section, HU 12 de Octubre, Madrid, Spain
3 shared publicationsAlejandro Ferrando
Radiation Oncology Department, Radiotherapy Section, HU 12 de Octubre, Madrid, Spain
2 shared publications- Angel Montero
Department of Radiation Oncology, Hospital Universitario HM Sanchinarro, Madrid, Spain
2 shared publications - Beatriz Álvarez
Department of Radiation Oncology, HM Hospitales, Madrid, Spain
2 shared publications Carmen Rubio
Radiation Oncology Department, HU HM Sanchinarro, HM Hospitales, c\ Oña n°10, 28050 Madrid, Spain
2 shared publications
Latest Publications
- Open Access
- 29 April 2022
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 22, 57-62
Intrafraction target shift comparison using two breath-hold systems in lung stereotactic body radiotherapy
- 29 April 2022
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 22, 57-62
Open AccessIntrafraction target shift comparison using two breath-hold systems in lung stereotactic body radiotherapy
- 1 August 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 161, S1235-S1236
PO-1508 Nonmalignant skeletal and soft tissue disorders: CT-based contouring atlas for low dose radiotherapy
- 1 August 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 161, S1235-S1236
PO-1508 Nonmalignant skeletal and soft tissue disorders: CT-based contouring atlas for low dose radiotherapy
- 1 August 2021
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1124) , 20200809
Radiotherapy CT-based contouring atlas for non-malignant skeletal and soft tissue disorders: a practical proposal from Spanish experience
Objective: Interest in low-dose radiotherapy (LD-RT) for the symptomatic treatment of nonmalignant conditions, including inflammatory and degenerative disorders of the joints and para-articular soft tissues, has increased substantially in recent years. In the present document, we provide a CT-based contouring atlas to help identify and delineate the most common osteoarticular regions susceptible to LD-RT. Methods: The clinical efficacy of LD-RT is supported by a large body of evidence. However, there is no consensus on the parameters for contouring the planning target volume (PTV). Moreover, 3D simulation and planning should be the standard of care even for nonmalignant disorders. For this reason, the present guidelines were prepared to help guide PTV contouring based on CT images, with the same quality criteria for patient immobilization, treatment simulation, planning and delivery as those routinely applied for cancer radiotherapy. Results: PTV for radiotherapy requires precise identification of the target areas based on CT and other imaging techniques. Using a series of cases treated at our institution, we have defined the PTVs for each location on the simulation CT to establish the relationship between the image and the anatomical structures to be treated. We also specify the immobilization systems used to ensure treatment accuracy and reproducibility. Conclusions: This comprehensive atlas based on CT images may be of value to radiation oncologists who wish to use LD-RT for the symptomatic treatment of degenerative or inflammatory osteoarticular diseases. Advances in knowledge: The recommendations and contouring atlas described in this article provide an eminently practical tool for LD-RT in non-malignant conditions, based on the same quality criteria recommended for all modern radiotherapy treatments in Spain.
- 1 August 2021
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1124) , 20200809
Radiotherapy CT-based contouring atlas for non-malignant skeletal and soft tissue disorders: a practical proposal from Spanish experience
Objective: Interest in low-dose radiotherapy (LD-RT) for the symptomatic treatment of nonmalignant conditions, including inflammatory and degenerative disorders of the joints and para-articular soft tissues, has increased substantially in recent years. In the present document, we provide a CT-based contouring atlas to help identify and delineate the most common osteoarticular regions susceptible to LD-RT. Methods: The clinical efficacy of LD-RT is supported by a large body of evidence. However, there is no consensus on the parameters for contouring the planning target volume (PTV). Moreover, 3D simulation and planning should be the standard of care even for nonmalignant disorders. For this reason, the present guidelines were prepared to help guide PTV contouring based on CT images, with the same quality criteria for patient immobilization, treatment simulation, planning and delivery as those routinely applied for cancer radiotherapy. Results: PTV for radiotherapy requires precise identification of the target areas based on CT and other imaging techniques. Using a series of cases treated at our institution, we have defined the PTVs for each location on the simulation CT to establish the relationship between the image and the anatomical structures to be treated. We also specify the immobilization systems used to ensure treatment accuracy and reproducibility. Conclusions: This comprehensive atlas based on CT images may be of value to radiation oncologists who wish to use LD-RT for the symptomatic treatment of degenerative or inflammatory osteoarticular diseases. Advances in knowledge: The recommendations and contouring atlas described in this article provide an eminently practical tool for LD-RT in non-malignant conditions, based on the same quality criteria recommended for all modern radiotherapy treatments in Spain.
- Open Access
- 1 January 2021
- Published by Termedia Sp. z.o.o.
- Vol. 26 (4) , 605-615
Radiation therapy with curative intention in men with de novo metastatic prostate carcinoma: shoot'em all!
Background: About 5% of prostate cancer cases are metastatic at diagnoses. Radiotherapy of both primary tumor and secondary lesions can be, in addition to systemic treatments, a radical alternative for selected patients. Materials and methods: Patients with de novo prostate carcinoma with bone or lymph node metastases were retrospectively reviewed. All patients received moderate hypofractionated IMRT/VMAT up to 63 Gy in 21 daily fractions of 3 Gy to prostate and metastases with neoadjuvant and concurrent androgen deprivation therapy (ADT). According to known advances some patients also received abiraterone, enzalutamide, or docetaxel. Results: Between 2015-2020, we attended 26 prostate cancer patients (median age 69.5 years, range 52-84) with simultaneous oligometastases (mean 2.1 metastases, median 1.5 metastases (range 1-6)1. Eighteen patients (69%) presented lymph node metastases, 4 (15.5%) bone metastases and 4 (15.5%) both lymph node and bone metastases. With a median follow-up of 15.5 months (range 3-65 months), 16 patients (62%) are alive and tumor free while 10 (38%) are alive with tumor. Four patients (17%) developed tumor progression, out of irradiated area in all cases, with a median time to progression of 43.5 months (range 27-56 months). Actuarial progression-free survival (PFS) rates at 12 and 24 months were 94.1% and 84.7%, respectively. No grade > 2 acute or late complications were recorded. Conclusions: Simultaneous directed radical hypofractionated radiation therapy for prostate and metastases is feasible, well tolerated and achieves an acceptable PFS rate. However, further studies with longer follow-up are necessary to definitively address these observations.
- 1 January 2021
- Published by Termedia Sp. z.o.o.
- Vol. 26 (4) , 605-615
Open AccessRadiation therapy with curative intention in men with de novo metastatic prostate carcinoma: shoot'em all!
Background: About 5% of prostate cancer cases are metastatic at diagnoses. Radiotherapy of both primary tumor and secondary lesions can be, in addition to systemic treatments, a radical alternative for selected patients. Materials and methods: Patients with de novo prostate carcinoma with bone or lymph node metastases were retrospectively reviewed. All patients received moderate hypofractionated IMRT/VMAT up to 63 Gy in 21 daily fractions of 3 Gy to prostate and metastases with neoadjuvant and concurrent androgen deprivation therapy (ADT). According to known advances some patients also received abiraterone, enzalutamide, or docetaxel. Results: Between 2015-2020, we attended 26 prostate cancer patients (median age 69.5 years, range 52-84) with simultaneous oligometastases (mean 2.1 metastases, median 1.5 metastases (range 1-6)1. Eighteen patients (69%) presented lymph node metastases, 4 (15.5%) bone metastases and 4 (15.5%) both lymph node and bone metastases. With a median follow-up of 15.5 months (range 3-65 months), 16 patients (62%) are alive and tumor free while 10 (38%) are alive with tumor. Four patients (17%) developed tumor progression, out of irradiated area in all cases, with a median time to progression of 43.5 months (range 27-56 months). Actuarial progression-free survival (PFS) rates at 12 and 24 months were 94.1% and 84.7%, respectively. No grade > 2 acute or late complications were recorded. Conclusions: Simultaneous directed radical hypofractionated radiation therapy for prostate and metastases is feasible, well tolerated and achieves an acceptable PFS rate. However, further studies with longer follow-up are necessary to definitively address these observations.
- 1 March 2019
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 24 (2) , 227-232
Performance of the eclipse monitor unit objective tool utilizing volumetric modulated arc therapy for rectal cancer
To assess the performance of the monitor unit (MU) Objective tool in Eclipse treatment planning system (TPS) utilizing volumetric modulated arc therapy (VMAT) for rectal cancer. Eclipse VMAT planning module includes a tool to control the number of MUs delivered: the MU Objective tool. This tool could be utilized to reduce the total number of MUs in rectal cancer treatments. 20 rectal cancer patients were retrospectively studied using VMAT and the MU Objective tool. The baseline plan for each patient was selected as the one with no usage of the MU Objective tool. The number of MUs of this plan was set to be the reference number of MUs (MUref). Five plans were re-optimized for each patient only varying the Max MU parameter. The selected values were 30%, 60%, 90%, 120% and 150% of MUref for each patient. Differences with respect to the baseline plan were evaluated regarding MU number and parameters for PTVs coverage evaluation, PTVs homogeneity and OARs doses assessment. A two-tailed, paired-samples t-test was used to quantify these differences. Average relative differences in MU number obtained was 10% for Max MU values of 30% and 60% of MUref, respectively (p < 0.03). PTVs coverage and homogeneity were not compromised and discrepancies obtained with respect to baseline plans were not significant. Furthermore, maximum OARs doses deviations were also not significant. A 10% reduction in the MU number could be obtained without an alteration of PTV coverage and OARs doses for rectal cancer.
- 1 March 2019
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 24 (2) , 227-232
Performance of the eclipse monitor unit objective tool utilizing volumetric modulated arc therapy for rectal cancer
To assess the performance of the monitor unit (MU) Objective tool in Eclipse treatment planning system (TPS) utilizing volumetric modulated arc therapy (VMAT) for rectal cancer. Eclipse VMAT planning module includes a tool to control the number of MUs delivered: the MU Objective tool. This tool could be utilized to reduce the total number of MUs in rectal cancer treatments. 20 rectal cancer patients were retrospectively studied using VMAT and the MU Objective tool. The baseline plan for each patient was selected as the one with no usage of the MU Objective tool. The number of MUs of this plan was set to be the reference number of MUs (MUref). Five plans were re-optimized for each patient only varying the Max MU parameter. The selected values were 30%, 60%, 90%, 120% and 150% of MUref for each patient. Differences with respect to the baseline plan were evaluated regarding MU number and parameters for PTVs coverage evaluation, PTVs homogeneity and OARs doses assessment. A two-tailed, paired-samples t-test was used to quantify these differences. Average relative differences in MU number obtained was 10% for Max MU values of 30% and 60% of MUref, respectively (p < 0.03). PTVs coverage and homogeneity were not compromised and discrepancies obtained with respect to baseline plans were not significant. Furthermore, maximum OARs doses deviations were also not significant. A 10% reduction in the MU number could be obtained without an alteration of PTV coverage and OARs doses for rectal cancer.
- Open Access
- 1 January 2019
- Published by Medknow in Journal of Medical Physics
- Vol. 44 (1) , 1-8
Dosimetric comparison of four volumetric-modulated arc therapy beam arrangements utilized for hippocampal-sparing whole-brain radiation therapy
Purpose: In the present study, the performance of four VMAT beam arrangements used for hippocampal-sparing whole-brain radiation therapy is addressed. Material and Methods: Data corresponding to 20 patients were utilized so as to generate plans for every beam configuration. A preliminary study was conducted to assess the optimal distance between optimization structures (PTVx) and hippocampi. V25, V30, D50%, D2%, D98%, homogeneity index (HI) and Paddick conformity factor (CF) were evaluated for PTV. D100% and Dmax were considered for hippocampi. All plans were required to perform at least as recommended in RTOG 0933 trial regarding organs at risk (OAR) sparing and PTV objectives. Results: Considerable hippocampi sparing alongside with a reasonably low decrease in PTV coverage was achieved using a 7 mm distance between hippocampi and PTV optimization structure. Beam setup 3 (comprised of two full arcs with 0° couch angle and two half arcs with 90° couch angle) achieved the best PTV coverage, HI and CF, while it performed the second-best sparing in hippocampi and lenses. Moreover, beam setup 3 was the second-fastest treatment, although it resulted in the highest number of delivered MU among all beam setups. Beam setup 1 (comprised of two full arcs with no couch angles) was the fastest and it delivered a significantly less amount of monitor units compared with the other beam setups evaluated. Furthermore, a higher robustness was obtained by using no couch angles. Although beam setup 1 was the least optimal considering OAR sparing, it still performed better than required in the RTOG 0933 trial. Conclusions: Overall, beam setup 3 was considered to be the best. It is worth mentioning that, apart from our results, the election of one of these beam arrangements might be dependent on the amount of patient workload at a specific institution.
- 1 January 2019
- Published by Medknow in Journal of Medical Physics
- Vol. 44 (1) , 1-8
Open AccessDosimetric comparison of four volumetric-modulated arc therapy beam arrangements utilized for hippocampal-sparing whole-brain radiation therapy
Purpose: In the present study, the performance of four VMAT beam arrangements used for hippocampal-sparing whole-brain radiation therapy is addressed. Material and Methods: Data corresponding to 20 patients were utilized so as to generate plans for every beam configuration. A preliminary study was conducted to assess the optimal distance between optimization structures (PTVx) and hippocampi. V25, V30, D50%, D2%, D98%, homogeneity index (HI) and Paddick conformity factor (CF) were evaluated for PTV. D100% and Dmax were considered for hippocampi. All plans were required to perform at least as recommended in RTOG 0933 trial regarding organs at risk (OAR) sparing and PTV objectives. Results: Considerable hippocampi sparing alongside with a reasonably low decrease in PTV coverage was achieved using a 7 mm distance between hippocampi and PTV optimization structure. Beam setup 3 (comprised of two full arcs with 0° couch angle and two half arcs with 90° couch angle) achieved the best PTV coverage, HI and CF, while it performed the second-best sparing in hippocampi and lenses. Moreover, beam setup 3 was the second-fastest treatment, although it resulted in the highest number of delivered MU among all beam setups. Beam setup 1 (comprised of two full arcs with no couch angles) was the fastest and it delivered a significantly less amount of monitor units compared with the other beam setups evaluated. Furthermore, a higher robustness was obtained by using no couch angles. Although beam setup 1 was the least optimal considering OAR sparing, it still performed better than required in the RTOG 0933 trial. Conclusions: Overall, beam setup 3 was considered to be the best. It is worth mentioning that, apart from our results, the election of one of these beam arrangements might be dependent on the amount of patient workload at a specific institution.
- 1 July 2018
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 4 (4) , 045042
Dosimetric characterization of a 5 mm diameter BrainLab cone for radiosurgery
Purpose . A dosimetric characterization of a 5 mm diameter cone is presented. PDD curves, dose profiles (OAR) and output factors ( S cp ) were measured utilizing different detectors. S cp values were obtained using distinct methodologies and they were compared to the new gold standard established by TRS-483 IAEA (2017). Methods . A procedure to align the detector axis of motion and the central axis for PDD determination is described. Four ionization chambers (PTW Farmer 30013, PTW Pin Point 31014, IBA CC 01 and IBA CC 04), a stereotactic diode (IBA SFD), EBT3 radiochromic film and TLD-600 Micro Cubes were used. For S cp determination five methodologies were considered: direct measurement method ( DMM ), intermediate field size method ( IFSM ), Monte Carlo correction factor method ( CFM ), BrainLab recommended method ( BLM ) and scanning chamber method ( SCM ), described by Fan et al (2009 Med. Phys. 36 5292–5300). SFD results were compared to Monte Carlo simulations. Results . PDD curves obtained satisfactorily agree (p < 6.4 · 10 −3 ). The best results for OARs were obtained using high spatial resolution devices, namely EBT3 and SFD diode. A 0.666 value was obtained for S cp as of an average of SFD and CC01 detector results utilizing TRS-483 new methodology. Differences between both results were less than 0.5%, showing how robust the new methodology is. SCM, BLM and EBT3 measurement achieved the most similar results with respect to TRS-483 obtained result (discrepancies of 1.7%, 0.1% and 3.7%, respectively). Besides, Monte Carlo result obtained (0.673) perfectly agrees with these methods results. Conclusions . A multidetector study was performed to obtain the main dosimetric functions to characterize a 5 mm radiosurgery cone. The use of ion chambers is not encouraged for OAR determination because of the important volume averaging effect, higher penumbras and steeper profile fall off nearby the maximum. Utilizing TRS-483 methodology we obtained a value of 0.666. SCM, BLM and EBT3 measurement are reliable procedures to obtain S cp values for very narrow beams due to their slight difference when compared to the new gold standard result.
- 1 July 2018
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 4 (4) , 045042
Dosimetric characterization of a 5 mm diameter BrainLab cone for radiosurgery
Purpose . A dosimetric characterization of a 5 mm diameter cone is presented. PDD curves, dose profiles (OAR) and output factors ( S cp ) were measured utilizing different detectors. S cp values were obtained using distinct methodologies and they were compared to the new gold standard established by TRS-483 IAEA (2017). Methods . A procedure to align the detector axis of motion and the central axis for PDD determination is described. Four ionization chambers (PTW Farmer 30013, PTW Pin Point 31014, IBA CC 01 and IBA CC 04), a stereotactic diode (IBA SFD), EBT3 radiochromic film and TLD-600 Micro Cubes were used. For S cp determination five methodologies were considered: direct measurement method ( DMM ), intermediate field size method ( IFSM ), Monte Carlo correction factor method ( CFM ), BrainLab recommended method ( BLM ) and scanning chamber method ( SCM ), described by Fan et al (2009 Med. Phys. 36 5292–5300). SFD results were compared to Monte Carlo simulations. Results . PDD curves obtained satisfactorily agree (p < 6.4 · 10 −3 ). The best results for OARs were obtained using high spatial resolution devices, namely EBT3 and SFD diode. A 0.666 value was obtained for S cp as of an average of SFD and CC01 detector results utilizing TRS-483 new methodology. Differences between both results were less than 0.5%, showing how robust the new methodology is. SCM, BLM and EBT3 measurement achieved the most similar results with respect to TRS-483 obtained result (discrepancies of 1.7%, 0.1% and 3.7%, respectively). Besides, Monte Carlo result obtained (0.673) perfectly agrees with these methods results. Conclusions . A multidetector study was performed to obtain the main dosimetric functions to characterize a 5 mm radiosurgery cone. The use of ion chambers is not encouraged for OAR determination because of the important volume averaging effect, higher penumbras and steeper profile fall off nearby the maximum. Utilizing TRS-483 methodology we obtained a value of 0.666. SCM, BLM and EBT3 measurement are reliable procedures to obtain S cp values for very narrow beams due to their slight difference when compared to the new gold standard result.